BACKGROUND: About 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival. METHODS: Gemcitabine (900 mg/m2) and docetaxel (35 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8 weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival. RESULTS: A total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16 months (95% confidence interval [CI], 8-24 months) compared to 12 months (95% CI, 8-16 months) for those without resection (p=0.276). The median recurrence-free survival rate after resection was 12 months (95% CI, 2-21 months). CONCLUSIONS: NeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis.
BACKGROUND: About 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival. METHODS:Gemcitabine (900 mg/m2) and docetaxel (35 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8 weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival. RESULTS: A total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16 months (95% confidence interval [CI], 8-24 months) compared to 12 months (95% CI, 8-16 months) for those without resection (p=0.276). The median recurrence-free survival rate after resection was 12 months (95% CI, 2-21 months). CONCLUSIONS: NeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis.
Authors: K Ridwelski; J Fahlke; R Kuhn; A Hribaschek; E Kettner; C Greiner; A Florschuetz; T Manger; G Wilhelm; H Klein; S Hahnfeld; H Lippert; F Meyer Journal: Eur J Surg Oncol Date: 2006-01-18 Impact factor: 4.424
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: S Kastl; T Brunner; O Herrmann; M Riepl; R Fietkau; G Grabenbauer; R Sauer; W Hohenberger; P Klein Journal: Eur J Surg Oncol Date: 2000-09 Impact factor: 4.424
Authors: William H Isacoff; Jacqueline K Bendetti; John J Barstis; Abdul-Rahman Jazieh; John S Macdonald; Philip A Philip Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544
Authors: Jon K Bjerregaard; Michael B Mortensen; Helle A Jensen; Claus Fristrup; Birgitte Svolgaard; Katrine R Schønnemann; Tine P Hansen; Morten Nielsen; Jørgen Johansen; Per Pfeiffer Journal: Radiother Oncol Date: 2009-05-10 Impact factor: 6.280
Authors: H Golcher; T Brunner; G Grabenbauer; S Merkel; T Papadopoulos; W Hohenberger; T Meyer Journal: Eur J Surg Oncol Date: 2008-01-10 Impact factor: 4.424
Authors: Marc W Fromer; Jenci Hawthorne; Prejesh Philips; Michael E Egger; Charles R Scoggins; Kelly M McMasters; Robert C G Martin Journal: Ann Surg Oncol Date: 2021-06-04 Impact factor: 5.344
Authors: Odo Gangl; Klaus Sahora; Peter Kornprat; Christian Margreiter; Florian Primavesi; Evelyne Bareck; Martin Schindl; Friedrich Längle; Dietmar Öfner; Hans-Jörg Mischinger; Johann Pratschke; Michael Gnant; Reinhold Függer Journal: World J Surg Date: 2014-02 Impact factor: 3.352
Authors: Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad Journal: Ann Surg Oncol Date: 2013-02-23 Impact factor: 5.344